ReviR Therapeutics, a Brisbane, CA-based AI-enabled biotechnology company focused on developing small molecule RNA modulators for neurogenetic diseases, closed a $30m Series A financing.
The round, which brought total raised so far to $54m, was led by Lapam Capital with participation from existing investors CDH Investments, 5Y Capital, and Yael Capital, as well as new participants XtalPi and the Charcot-Marie Tooth Research Foundation (CMTRF).
The company intends to use the funds to further augment its AI-driven drug discovery VoyageR platform, which will be leveraged to advance proprietary chemical matter for novel and undruggable targets and to support clinical development of treatments for Huntington’s disease (HD), Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and other neurological disorders.
Founded in 2021 and led by Dr. Peng Yue, CEO, ReviR Therapeutics is an emerging biopharmaceutical company focused on the development of RNA-targeting small molecule therapies that modulate the causal genes of diseases, including CNS diseases, cancer, and other rare genetically-defined diseases. The company is utilizing technologies to develop therapies with the goal of developing disease modifying therapies that are highly specific, efficacious, and safe. The company’s initial focus is to apply SpliceR modulation technologies towards RNA targets of genetic diseases with limited or no treatment options.
FinSMEs
29/07/2024